Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety
References (26)
- et al.
Exploration of mice in a black and white test box: validation as a model of anxiety
Pharmacol. Biochem. Behav.
(1989) - et al.
Preliminary report of a simple animal behaviour model for the anxiolytic effects of benzodiazepines
Pharmacol. Biochem. Behav.
(1980) - et al.
Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors
Eur. J. Pharmacol.
(1989) - et al.
Characterization of [3H] CCK4 binding sites in mouse and rat brain
Neuropeptides
(1988) Distress vocalization in rat pups
A simple screening method for anxiolytic drugs
J. Pharmacol. Methods
(1985)- et al.
CCK-8-related C-terminal tetrapeptides: affinities for central CCKB and peripheral CCKA receptors
Eur. J. Pharmacol.
(1991) - et al.
CCK in animal and human research on anxiety
Trends Pharmacol. Sci.
(1993) - et al.
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
J. Neurosci. Methods
(1985) - et al.
Cholecystokinin and anxiety
TIPS
(1990) - et al.
Infant rat separation is a sensitive test for novel anxiolytics
Prog. Neuropsychopharmacol. Biol. Psychiatry
(1991)
A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety
Psychopharmacology
The cholecystokinin hypothesis of panic and anxiety disorders: a review
J. Psychopharmacol.
Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder
Clinical and behavioral findings
Arch. Gen. Psychiatry
Cited by (62)
Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer's and Parkinson's disease
2024, Frontiers in NeuroendocrinologyNeuropeptide Y attenuates anxiety- and depression-like effects of cholecystokinin-4 in mice
2014, NeuroscienceCitation Excerpt :CCK knock-down mice showed anxiolytic- and antidepressant-like effects (Del Boca et al., 2012). Several preclinical and clinical studies reported panicogenic and anxiogenic responses following the administration of CCK-4 (Singh et al., 1991; Bradwejn et al., 1994; Rex et al., 1994; van Megen et al., 1996; Holy and Wisniewski, 1998). In addition, treatment with CCK-B receptor antagonist elicited anxiolytic- (Singh et al., 1991; Derrien et al., 1994) and antidepressant-like responses (Hernando et al., 1994; Becker et al., 2008).
Anxiogenic effect of CCK8s in the ventral hippocampus of rats: Possible involvement of GABA<inf>A</inf> receptors
2012, Pharmacological ReportsCitation Excerpt :Bilateral injection of CCK8s into the ventral hippocampus, decreased %OAT and %OAE without affecting locomotor activity indicating a pure anxiogenic effect. The present finding is consistent with the results of previous studies in which anxiogenic responses following intraperitoneal [39, 48], intracerebroventricular [12], intra-central nucleus of amygdala [20], intra-periaqueductal grey [31] and intra-dorsal hippocampus [40] administration of CCK analogues have been reported. Moreover, the results of Pérez de la Mora et al. [34] showed that injection of either CCK4 or CCK8s into the rostrolateral amygdala promoted anxiogenic-like effects in the elevated plus-maze.
CCK as a modulator of cardiovascular function
2009, Journal of Chemical Neuroanatomy